IMP estimates 58b dong pre tax profit in H1/2012

In the first six months of 2012, Imexpham Pharmaceutical Joint Stock Co (coded IMP) estimated to gain 58 billion dong pre tax profit, fulfilling its 6-month plan and equalling 50 percent of the year’s plan, said Nguyen Quoc Dinh, deputy general director of IMP.

Currently, IMP’s key goal is to review operating costs and production costs to enhance the competitiveness and capital use efficiency. IMP is striving to achieve this year’s business plan with revenue of 890 billion dong, pre tax profit at 115 billion dong and dividend at 22%.

It is expected that in Q4/2012, the company’s Penicillin injection plant in Vietnam-Singapore II industrial zone, Binh Duong province will officially go into operation.

 

Category: Business